News | September 03, 2023
BioNTech to lead $2 billion mRNA-based oncology therapy market despite challenges, says GlobalData
BioNTech's diverse pipeline includes multiple drugs in Phase I, II, and III clinical trials
BioNTech's diverse pipeline includes multiple drugs in Phase I, II, and III clinical trials
KEYTRUDA is the first immunotherapy approved in the EU for the first-line treatment of this patient population
Deep Transcranial Magnetic Stimulation (dTMS) is a non-invasive brain stimulation technique approved by regulatory authorities, including the USFDA
Zydus' Indomethacin suppositories also been granted 180-day CGT exclusivity to market this product.
Jemperli is the only immuno-oncology treatment approved in the frontline setting for this patient population in combination with chemotherapy
If approved, KEYTRUDA would be the first immunotherapy for the first-line treatment of HER2-positive advanced gastric or GEJ cancer in tumors expressing PD-L1 (CPS ?1) in the EU
Mage Biologics to develop a monoclonal antibody targeting ulcerative colitis
Approval to dramatically change CAR-T therapies landscape
Collaboration to provide hospitals with a comprehensive offering across imaging and treatment for cancer patients requiring radiation therapy
Laurus will also provide funding for the clinical trials and will launch these products in India and emerging markets
Subscribe To Our Newsletter & Stay Updated
